Dr. Baiocchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
460 W 10th Ave
5th Floor
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-4812- Is this information wrong?
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
- Ohio State University HospitalResidency, Internal Medicine, 1999 - 2001
- Ohio State University College of MedicineClass of 1999
- SUNY BUffaloMD, medicine, 1995 - 1997
- State University of New York CollegePh.D, Physiology, 1994
- State University of New York CollegeM.S., Natural Science, 1993
- State University of New York CollegeB.S., Biology, 1989
Certifications & Licensure
- OH State Medical License 2000 - 2025
Awards, Honors, & Recognition
- Early Career Innovator of the Year Nomination The Ohio State University, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Innovation Award-Semi Finalist Inventor of the Year Nomination Tech Columbus, 2011
- Join now to see all
Clinical Trials
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
- Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease...Mahadeo, K., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., M...> ;The Lancet. Oncology. 2024 Mar 1
- Resistance to PRMT5-targeted therapy in mantle cell lymphoma.Mackenzie Elizabeth Long, Shirsha Koirala, Shelby Sloan, Fiona Brown-Burke, Christoph Weigel, Lynda Villagomez, Kara Corps, Archisha Sharma, Ian Hout, Margaret Harper,...> ;Blood Advances. 2024 Jan 9
- PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.Rodriguez, C., Kang, H., Babbar, N., Sun, W., Ferrarotto, R., Swiecicki, P., Zandberg, D., Baiocchi, R., Wesolowski, R., McKean, M., Monga, V., Nath, R., Palmisiano, N...> ;Oral Oncology. 2024 Feb 1
- Join now to see all
Journal Articles
- A Phase I study of Vorinostat maintenance after autologous transplant in high risk lymphomaHofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Pen..., Leuk Lymphoma, 1/1/2015
- The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and ref...Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Br J Haematol, 1/1/2015
- AIDS Malignancy Consortium AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphomaNoy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L, Blood, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 ActivityRobert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Post graduate career options for the physician scientistChicago, IL - 1/26/2015
- Targeting Histone Methyltransferases and Demethylases trackBoston, MA - 1/24/2015
- Join now to see all
Press Mentions
- OSU Doctor Looks into Viruses That May Lead to CancerMay 11th, 2019
- Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
- Possible New Target for Future Brain Cancer DrugsFebruary 27th, 2014
- Join now to see all
Grant Support
- Development Of Novel Compounds To Inhibit PRMT5 Enzyme In High Grade AstrocytomasNational Institute Of Neurological Disorders And Stroke2010–2011
- Development Of Vaccine Strategies To Prevent EBV+ Lymphoma In Patients With HIVNational Cancer Institute2009–2010
- Ptld: Cytokine Production And Gene PolymorphismsNational Cancer Institute2005
- Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2003
Hospital Affiliations
- The OSUCCC - JamesColumbus, Ohio
- Ohio State University Wexner Medical CenterColumbus, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: